Last reviewed · How we verify
LY2801653
At a glance
| Generic name | LY2801653 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer (PHASE2)
- A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (PHASE1)
- Merestinib In Non-Small Cell Lung Cancer And Solid Tumors (PHASE2)
- Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer (PHASE1)
- A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents (PHASE1)
- A Study of LY2801653 in Advanced Cancer (PHASE1)
- A Study of Merestinib (LY2801653) in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY2801653 CI brief — competitive landscape report
- LY2801653 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI